Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Acquires 5,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 5,000 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was bought at an average price of $3.46 per share, for a total transaction of $17,300.00. Following the acquisition, the chief executive officer owned 640,812 shares in the company, valued at $2,217,209.52. The trade was a 0.79% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Trading Up 1.7%

ANIX stock opened at $3.52 on Wednesday. The company has a market cap of $119.75 million, a PE ratio of -11.35 and a beta of 0.59. The stock has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $2.92. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. Equities analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. 683 Capital Management LLC acquired a new stake in Anixa Biosciences in the fourth quarter valued at approximately $355,000. ExodusPoint Capital Management LP purchased a new stake in shares of Anixa Biosciences during the fourth quarter valued at approximately $293,000. Susquehanna International Group LLP lifted its position in shares of Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares in the last quarter. Virtu Financial LLC acquired a new stake in Anixa Biosciences during the 4th quarter valued at $161,000. Finally, State Street Corp grew its holdings in Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock valued at $496,000 after purchasing an additional 38,540 shares in the last quarter. 29.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.